Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease
Open accessThe DOI matches its Crossref record.
Abstract
Background and Aims: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort. Models were constructed using baseline data, or data through week 6 of VDZ therapy. Results: The clinical trial included 594 subjects who received VDZ with baseline active inflammation [elevated C-reactive protein (>5 mg/L)]. Subjects with missing predictor variables (N = 120) or missing outcome data (N = 2) were excluded to produce a modeling dataset of 472 subjects. The Area Under the Receiver Operating Characteristic curve (AuROC) for corticosteroid-free biologic remission at week 52 using baseline data was only 0.65 (95% CI: 0.53 - 0.77), but was 0.75 (95% CI: 0.64 - 0.86) with data through week 6 of VDZ . Patients predicted to be in corticosteroid-free biologic remission at week 52 by the model achieved this endpoint 35.8% of the time, whereas patients predicted to fail only succeeded 6.7% of the time. Conclusions: An algorithm using laboratory data through week 6 of VDZ therapy was able to identify which CD patients with baseline inflammation would achieve corticosteroid-free biologic remission on VDZ at week 52. A majority of patients can be identified by week 6 as very unlikely to achieve remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Integration of Artificial Intelligence into Clinical Practice
Karalis, V. D. (2024) · Applied Biosciences · doi:10.3390/applbiosci3010002 · Cited by 255
“AI algorithms have undergone training to forecast the response to treatment and assess the likelihood of disease recurrence [63,64].”
BackgroundBig data in IBD: big progress for clinical practice
Seyed Tabib, N. S., Madgwick, M., Sudhakar, P., Verstockt, B., Korcsmaros, T., & Vermeire, S. (2020) · Gut · doi:10.1136/gutjnl-2019-320065 · Cited by 223
Gubatan, J., Levitte, S., Patel, A., Balabanis, T., Wei, M. T., & Sinha, S. R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1920 · Cited by 121
Machine learning predictive outcomes modeling in inflammatory bowel diseases
Javaid, A., Shahab, O., Adorno, W., Fernandes, P., May, E., & Syed, S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab187 · Cited by 36
Metadata
- Authors
- Waljee, A. K., Liu, B., Sauder, K., Zhu, J., Govani, S. M., Stidham, R. W., & Higgins, P. D. R.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-13
- Volume
- 24
- Issue
- 6
- Pages
- 1185-1192
- ISSN
- 1078-0998 (ISSN-L)
- 1536-4844
- OpenAlex
- W2798086101
- Cited by
- 68
- References
- 0
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease. https://app.cochat.ai/papers/10.1093/ibd/izy031
- The paper
- Waljee, A. K., Liu, B., Sauder, K., Zhu, J., Govani, S. M., Stidham, R. W., & Higgins, P. D. R. (2018). Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izy031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.